Aurinia Pharmaceuticals Inc.
AUPH
$15.99
$0.271.72%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 298.30M | 283.06M | 265.81M | 260.11M | 247.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 298.30M | 283.06M | 265.81M | 260.11M | 247.30M |
| Cost of Revenue | 77.58M | 77.92M | 65.48M | 63.32M | 61.76M |
| Gross Profit | 220.72M | 205.14M | 200.33M | 196.80M | 185.54M |
| SG&A Expenses | 103.48M | 101.79M | 109.57M | 125.76M | 144.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.32M | -170.00K | 16.00M | 19.64M | 10.11M |
| Total Operating Expenses | 163.99M | 166.79M | 184.70M | 197.00M | 204.83M |
| Operating Income | 134.30M | 116.26M | 81.10M | 63.11M | 42.47M |
| Income Before Tax | 133.73M | 114.16M | 79.64M | 62.49M | 41.81M |
| Income Tax Expenses | -164.48M | -173.05M | 1.80M | 1.85M | 1.96M |
| Earnings from Continuing Operations | 298.21 | 287.20 | 77.84 | 60.64 | 39.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 298.21M | 287.20M | 77.84M | 60.64M | 39.85M |
| EBIT | 134.30M | 116.26M | 81.10M | 63.11M | 42.47M |
| EBITDA | 153.71M | 135.71M | 100.55M | 82.58M | 61.92M |
| EPS Basic | 2.26 | 2.16 | 0.58 | 0.44 | 0.28 |
| Normalized Basic EPS | 0.63 | 0.54 | 0.44 | 0.36 | 0.26 |
| EPS Diluted | 2.16 | 2.07 | 0.56 | 0.43 | 0.28 |
| Normalized Diluted EPS | 0.61 | 0.52 | 0.43 | 0.35 | 0.26 |
| Average Basic Shares Outstanding | 531.00M | 537.54M | 547.78M | 559.02M | 567.47M |
| Average Diluted Shares Outstanding | 549.33M | 554.89M | 564.41M | 574.05M | 580.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |